Minor Cannabinoids Look Promising for Cancer Says New Study
CBG, CBC, CBN, & CBDV were found to inhibit MM cell growth
Cannabinoids are now being prescribed to palliative cancer patients in an attempt to control symptoms, as well as side effects of treatments like chemotherapy.
Until now, the majority of research has focused on CBD and THC. A new study however suggests that some minor cannabinoids may also have anti-cancer properties.
Which Minor Cannabinoids Were Involved in the Test?
In a new study researchers have identified the anti-cancer effects of Cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV). All of these minor cannabinoids have been found to have an anti-cancer effect on a type of bone marrow cancer called multiple myeloma.
Multiple Myeloma usually affects multiple parts of the body, like the skull, spine, pelvis and ribs. Currently, there is no cure, and whilst some people live for many years with the diagnosis, patients can become resistant to all known treatments.
In the study, CBG, CBC, CBN, and CBDV were examined and it was found that they ‘inhibited MM cell growth, in a dose-dependent manner’. CBN and CBDV were pinpointed as the most productive in reducing cell viability.
CBG, CBC, CBN, and CBDV were also found to lessen the attack of MM cells on osteoblast cells. Osteoblasts are cells which form new bones and increase existing bone tissue–and bone resorption.
Previous studies conducted reinforce the conclusions that cannabinoids can reduce tumour growth in vivo and that CBG distinctly has been shown to decrease tumour growth in a rodent model of melanoma. Further study is required however to allow for a better understanding of how cannabinoids work in the body individually and collectively.
More From Soft Secrets:
L
Liz Filmer
